Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery

References

• Wainwright M, Amaral L. The phenothiazinium chromophore and the evolution of antimalarial drugs. Trop. Med. Int. Health10(6), 501–511 (2005).
   PubMed Web of Science ®Google Scholar
• Harvey BH, Duvenhage I, Viljoen F et al. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem. Pharmacol.80(10), 1580–1591 (2010).
   PubMed Web of Science ®Google Scholar
• Schirmer RH, Adler H, Pickhardt M, Mandelkow E. “Lest we forget you – methylene blue…” Neurobiol. Aging32(12), 2325.e7–e16 (2011).
   PubMed Web of Science ®Google Scholar
• Stawicki SP, Sims C, Sarani B, Grossman MD, Gracias VH. Methylene blue and vasoplegia: who, when, and how? Mini Rev. Med. Chem.8(5), 472–490 (2008).
   PubMed Web of Science ®Google Scholar
• Shanmugan G. Vasoplegic syndrome – the role of methylene blue. Eur. J. Cardiothorac. Surg.28(5), 705–710 (2005).
   PubMed Web of Science ®Google Scholar
• Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol.56(3), 247–250 (2000).
   PubMed Web of Science ®Google Scholar
• Ozal E, Kuralay E, Yildirim V et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann. Thorac. Surg.79(5), 1615–1619 (2005).
   PubMed Web of Science ®Google Scholar
• Evora PR, Roselino CH, Schiaveto PM. Methylene blue in anaphylactic shock. Ann. Emerg. Med.30(2), 240 (1997).
   PubMed Web of Science ®Google Scholar
• Evora PR. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? J. Thorac. Cardiovasc. Surg.119(3), 195–196 (2000).
   Google Scholar
• Almeida JA, Riordan SM, Liu J et al. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur. J. Gastroenterol. Hepatol.19(4), 341–346 (2007).
   PubMed Web of Science ®Google Scholar
• Clifton J, Leikin J. Methylene blue. Am. J. Ther.10(4), 289–291 (2003).
   PubMedGoogle Scholar
• Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J. Psychopharmacol.24(10), 1433–1438 (2010).
   PubMed Web of Science ®Google Scholar
• Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br. J. Pharmacol.152(6), 946–951 (2007).
   PubMed Web of Science ®Google Scholar
• Oz M, Isaev D, Lorke DE, Hasan M, Petroianu G, Shippenberg TS. Methylene blue inhibits serotonin transporter function. Br. J. Pharmacol. doi:10.1111/j.1476–5381.2011.01462.x (2011) (Epub ahead of print).
   Google Scholar
• Jangjoo A, Forghani MN, Mehrabibahar M, Sadeghi R. Anaphylaxis reaction of a breast cancer patient to methylene blue during breast surgery with sentinel node mapping. Acta Oncol.49(6), 877–878 (2010).
   PubMed Web of Science ®Google Scholar
• Dewachter P, Castro S, Nicaise-Roland P et al. Anaphylactic reaction after methylene blue-treated plasma transfusion. Br. J. Anaesth.106(5), 687–689 (2011).
   PubMed Web of Science ®Google Scholar
• Nubret K, Delhoume M, Orsel I, Laudy JS, Sellami M, Nathan N. Anaphylactic shock to fresh–frozen plasma inactivated with methylene blue. Transfusion51(1), 125–128 (2011).
   PubMed Web of Science ®Google Scholar
• Telgenkamp B, Japink D, van Haaren E. Cardiac arrest after patent blue v injection for sentinel lymph node biopsy in breast cancer. Breast Care5(6), 411–413 (2010).
   PubMed Web of Science ®Google Scholar
• Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res. A Clin. Mol. Teratol.67(2), 133–140 (2003).
   PubMed Web of Science ®Google Scholar
• Ozal E, Kuralay E, Yildirim V et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann. Thorac. Surg.79(5), 1615–1619 (2005).
   PubMed Web of Science ®Google Scholar
• Levin RL, Degrange MA, Bruno GF et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann. Thorac. Surg.77(2), 496–499 (2004).
   PubMed Web of Science ®Google Scholar
• Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation120(17), 1664–1671 (2009).
   PubMed Web of Science ®Google Scholar
• Argenziano M, Chen JM, Choudhri AF et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J. Thorac. Cardiovasc. Surg.116(6), 973–980 (1998).
   PubMed Web of Science ®Google Scholar
• Sun X, Zhang L, Hill PC et al. Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? Eur. J. Cardiothorac. Surg.34(4), 820–825 (2008).
   PubMed Web of Science ®Google Scholar
• Brasil LA, Gomes WJ, Salomão R, Buffolo E. Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass. Ann. Thorac. Surg.66(1), 56–59 (1998).
   PubMed Web of Science ®Google Scholar
• Aydin NB, Gercekoglu H, Aksu B et al. Endotoxemia in coronary artery bypass surgery: a comparison of the off-pump technique and conventional cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.125(4), 843–848 (2003).
   PubMed Web of Science ®Google Scholar
• Mekontso-Dessap A, Houël R, Soustelle C, Kirsch M, Thébert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann. Thorac. Surg.71(5), 1428–1432 (2001).
   PubMed Web of Science ®Google Scholar
• Byrne JG, Leacche M, Paul S et al. Risk factors and outcomes for ‘vasoplegia syndrome’ following cardiac transplantation. Eur. J. Cardiothorac. Surg.25(3), 327–332 (2004).
   PubMed Web of Science ®Google Scholar
• Gomes WJ, Carvalho AC, Palma JH et al. Vasoplegic syndrome after open heart surgery. J. Cardiovasc. Surg. (Torino)39(5), 619–623 (1998).
   PubMed Web of Science ®Google Scholar
• Gkaliakousi E, Ferro A. Nitric oxide signaling in the regulation of cardiovascular and platelet function. Front. Biosci.16, 1873–1897 (2011).
   Web of Science ®Google Scholar
• Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett.275(1–2), 87–90 (1990).
   PubMed Web of Science ®Google Scholar
• Kilbourn RG, Gross SS, Jubran A et al. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl Acad. Sci. USA87(9), 3629–3632 (1990).
   PubMed Web of Science ®Google Scholar
• Beasley D, McGuiggin M. Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J. Exp. Med.179(1), 71–80 (1994).
   PubMed Web of Science ®Google Scholar
• Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J. Immunother.34(5), 419–427 (2011).
   PubMed Web of Science ®Google Scholar
• Schmidt HH. NO., CO and OH. Endogenous soluble guanylyl cyclase-activating factors. FEBS Lett.307(1), 102–107 (1992).
   PubMed Web of Science ®Google Scholar
• Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin. Thorac. Cardiovasc. Surg.22(2), 140–144 (2010).
   PubMedGoogle Scholar
• Bester AM, Harvey BH. Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements. Metab. Brain Dis.15(4), 275–285 (2000).
   PubMed Web of Science ®Google Scholar
• Lomniczi A, Cebral E, Canteros G, McCann SM, Rettori V. Methylene blue inhibits the increase of inducible nitric oxide synthase activity induced by stress and lipopolysaccharide in the medial basal hypothalamus of rats. Neuroimmunomodulation8(3), 122–127 (2000).
   PubMed Web of Science ®Google Scholar
• Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur. Heart J.14(Suppl. I), 22–26 (1993).
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, Wood KS, Ignarro LJ. Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch. Biochem. Biophys.218(1), 187–198 (1982).
   PubMed Web of Science ®Google Scholar
• Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol.50(1), 1–5 (1996).
   PubMed Web of Science ®Google Scholar
• Evora PR, Ribeiro PJ, Vicente WV et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev. Bras. Cir. Cardiovasc.24(3), 279–288 (2009).
   PubMed Web of Science ®Google Scholar
• Leyh RG, Kofidis T, Strüber M et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J. Thorac. Cardiovasc. Surg.125(6), 1426–1431 (2003).
   PubMed Web of Science ®Google Scholar
• Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth. Analg.103(1), 2–8 (2006).
   PubMed Web of Science ®Google Scholar
• McRobb CM, Holt DW. Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review. J. Extra. Corpor. Technol.40(3), 206–214 (2008).
   PubMedGoogle Scholar
• Taylor K, Holtby H. Methylene blue revisited: management of hypotension in a pediatric patient with bacterial endocarditis. J. Thorac. Cardiovasc. Surg.130(2), 566 (2005).
   PubMed Web of Science ®Google Scholar
• Weissgerber AJ. Methylene blue for refractory hypotension: a case report. AANA J.76(4), 271–274 (2008).
   PubMedGoogle Scholar
• Andritsos MJ. Con: methylene blue should not be used routinely for vasoplegia perioperatively. J. Cardiothorac. Vasc. Anesth.25(4), 739–743 (2011).
   PubMed Web of Science ®Google Scholar
• Riha H, Augoustides JG. Pro: methylene blue as a rescue therapy for vasoplegia after cardiac surgery. J. Cardiothorac. Vasc. Anesth.25(4), 736–738 (2011).
   PubMed Web of Science ®Google Scholar
• Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg.118(1), 195–196 (1999).
   PubMed Web of Science ®Google Scholar
• Pagni S, Austin EH. Use of intravenous methylene blue for the treatment of refractory hypotension after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg.119(6), 1297–1298 (2000).
   PubMed Web of Science ®Google Scholar
• Kofidis T, Strüber M, Wilhelmi M et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J. Thorac. Cardiovasc. Surg.122(4), 823–824 (2001).
   PubMed Web of Science ®Google Scholar
• Dagenais F, Mathieu P. Rescue therapy with methylene blue in systemic inflammatory response syndrome after cardiac surgery. Can. J. Cardiol.19(2), 167–169 (2003).
   PubMed Web of Science ®Google Scholar
• Mora-Ordóñez JM, Sánchez-Llorente F, Galeas-López JL, Hernández Sierra B, Prieto-Palomino MA, Vera-Almazán A. Use of methylene blue in the treatment of vasoplegic syndrome of post-operative heart surgery. Med. Intensiva.30(6), 293–296 (2006).
   PubMedGoogle Scholar
• Del Duca D, Sheth SS, Clarke AE, Lachapelle KJ, Ergina PL. Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann. Thorac. Surg.87(2), 640–642 (2009).
   PubMed Web of Science ®Google Scholar